Bio News
Hypera Pharma will launch its synthetic semaglutide product, ‘Semavi,’ in the Brazilian market at the end of September. Hypera Pharma received price approval for the product from Brazil’s Chamber of Regulation of the Medicines Market (CMED). The company plans to improve patient access through affordable pricing in the GLP-1 market, which is expected to reach $183 billion (approximately 260 trillion won) by 2030.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
